Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PI-CaP: PIPAC with Oxaliplatin, Cisplatin, and Doxorubicin for Peritoneal Carcinomatosis
NCT02604784Phase 2Completed
- Sponsor
- Fondazione del Piemonte per l'Oncologia
- Start
- Oct 2015
- Primary completion
- May 2020
- Modality
- DNA Intercalators/Alkylators, Targeted Liposomes, Stealth (PEGylated) Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of oxaliplatin, Cisplatin micelle injection (HA132), pegylated liposomal doxorubicin in peritoneal carcinomatosis (PC), sponsored by Fondazione del Piemonte per l'Oncologia. Started Oct 2015; status: completed.
02
Drugs
oxaliplatinCisplatin micelle injection (HA132)pegylated liposomal doxorubicin
03
Conditions
peritoneal carcinomatosis (PC)
Beyond the preview
Go deeper on NCT02604784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02604784.